These contradictory findings may be at least partially explained by the findings by Wang et al., which report that SRPK1 can function as both an oncogene and a tumor suppressor by modulating the PH domain leucine-rich repeat protein phosphatases (PHLPP)-mediated dephosphorylation of protein kinase B [42], its highly likely that the PHLPP-mediated downstream pathways may also participated in the chemotherapy-resistance. This evidence concerns the gene SRPK1 and neoplasm.